Want to see HUMA full AI Analyst Report?
HUMA Stock Chart & Stats
$0.70
-$0.01(-2.16%)
At close: 4:00 PM EDT
$0.70
-$0.01(-2.16%)
Day’s Range― - ―
52-Week Range$0.53 - $2.55
Previous CloseN/A
Volume2.57M
Average Volume (3M)7.88M
Market Cap
$168.04M
Enterprise Value$168.89
Total Cash (Recent Filing)$79.90M
Total Debt (Recent Filing)$66.18M
Price to Earnings (P/E)―
Beta3.21
Next Earnings
Nov 06, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding277,798,100
10 Day Avg. Volume6,430,196
30 Day Avg. Volume7,880,520
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.06Price Target Upside194.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$3.50M
Bulls Say, Bears Say
Bulls Say
Strong Phase III EfficacyThe statistically significant Phase III interim result supports a clinically differentiated vascular-access product, with more catheter-free time and fewer infections than the comparator. If sustained through regulatory review, these outcomes could strengthen adoption among physicians, hospitals, and payers.
Regulatory And Pipeline ProgressA defined sBLA timetable, potential priority review, and an accepted IND create multiple advancing regulatory pathways for the tissue-engineering platform. This progress can expand the addressable opportunity beyond the current product while providing identifiable milestones over the next several quarters.
Early Commercialization MomentumEarly product revenue and health-system adoption indicate that commercialization is beginning to move beyond clinical development. Broader account penetration and increasing use at early adopter sites could establish a repeatable hospital sales channel as regulatory indications and physician familiarity expand.
Bears Say
Heavy Operating LossesThe company remains far from self-funded profitability, as limited revenue is outweighed by research, development, commercial, and corporate costs. Persistently large losses reduce financial flexibility and make successful product scaling and regulatory execution essential to improving the earnings profile.
Substantial Cash BurnOngoing cash outflows show that the current business has not yet generated enough operating cash to fund its activities. Continued clinical and commercial investment may therefore require additional financing, increasing dependence on capital markets before product revenue reaches a larger scale.
Leverage And Inconsistent Equity BaseElevated leverage and a historically unstable equity base constrain balance-sheet flexibility while the company funds loss-making operations. Debt obligations can limit future capital-allocation choices and amplify the consequences of delays in regulatory approval, adoption, or commercialization.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.53 and its highest was $2.55 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $168.04M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Nov 06, 2026 which is in 58 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Aug 12, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.113 by -$0.047.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.09.
How many shares outstanding does Humacyte have?
Humacyte has 277,798,100 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.113. Following the earnings report the stock price went down -6.338%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.06 (194.64% Upside)
$2.06 (194.64% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Humacyte
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
HUMA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum (statistically significant V012 results, planned sBLA filing, IND acceptance for CTEV, commercial team overhaul and early commercial traction) which are material positives. However, near-term financials showed modest absolute sales, rising COGS and inventory reserves, a substantial six‑month loss driven by non-cash liability remeasurements, and continued operating spend. The operational and clinical progress appears to materially outweigh the current financial headwinds, which management is positioning to address as commercialization scales.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$2.06
▲(194.64% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
7.91% Insiders
4.66% Mutual Funds
11.12% Other Institutional Investors
71.28% Public Companies and
Individual Investors